Monica Jong, OD, PhD, FAAO, FBCLA, discussed how recent developments in the field of myopia will transform eye care providers' approach to management.
News|Articles|September 8, 2026
Monthly pipeline update: August 2026
Author(s)Anita Shiva
Fact checked by: Kirsty Mackay
The latest in drug and technology developments and updates from August 2026.
Advertisement
Advertisement
This August, the long-awaited approval of Lytenava (bevacizumab-vikg; Outlook Therapeutics) changed the landscape of neovascular age-related macular degeneration (AMD) treatment. Major updates in dry eye, lens technology, and glaucoma treatment also took the spotlight. Learn the latest in pipeline news from our roundup below:
Related to this article
Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."
Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.
Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
Advertisement
Advertisement